Concerns Raised Over FDA Advisory Panel's Endorsement of Multi-Cancer Screening Test

A viewpoint published in STAT News criticizes an FDA advisory council's recommendation to approve Grail's Galleri multi-cancer blood test, arguing that the test 'flunked its own big trial' and could lead to increased false positives and wasted resources. The author, H. Gilbert Welch, a physician and cancer screening researcher, emphasizes that the only metric that truly matters is whether fewer people die.